Oleanane-24-Esters Inhibit Cancer Invasion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly for various types of cancers such as breast, leukocytic, liver, ovarian, and others, lack effective inhibitors for cancer invasion, metastasis, and cell adhesion, which are critical for controlling tumor progression and spread.
Innovation Solution
Development of specific compounds that modulate adhesion proteins and angiopoietins, inhibiting excess adhesion and cell attachment, and affecting gene expression to inhibit cancer growth, invasion, and metastasis, using structures derived from esterification of core compounds with functional groups like Tigloyl, Angeloyl, and others, which are synthesized and tested for their anti-cancer properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then general cancer therapy is provided, but effective inhibition of cancer invasion, metastasis, and cell adhesion is lacking
Solution Approach 1:
The patent modifies the chemical structure of oleanane compounds by introducing specific ester groups at position 24, creating new derivatives with enhanced anti-invasive and anti-metastatic activities. This structural parameter change resolves the contradiction by providing compounds that specifically target cancer invasion and metastasis while maintaining therapeutic efficacy.
Solution Approach 2:
The invention combines the oleanane core structure with various ester functional groups (such as tigloyl, angeloyl, feruloyl groups) to create composite molecular structures. These composite compounds exhibit synergistic effects, providing both anti-cancer and anti-invasive properties that overcome the limitations of current treatments.
2Reliability
If new oleanane-24-ester compounds are developed, then inhibition of cancer invasion and metastasis is achieved, but compound complexity increases
Solution Approach 1:
The patent segments the molecular structure into a stable oleanane core and variable ester side chains. This segmentation allows the core structure to maintain stability while the side chains provide diverse bioactive functions, resolving the contradiction between effectiveness and complexity by modularizing the compound design.
Solution Approach 2:
The invention introduces specific functional ester groups at the 24-position of the oleanane skeleton, creating local structural variations that confer anti-invasive and anti-metastatic activities. This local modification approach maintains the overall simplicity of the core structure while adding specific functional complexity where needed.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases.